Navigation Links
Alba Therapeutics Corporation Announces Promotions
Date:10/2/2008

BALTIMORE, Oct. 2 /PRNewswire/ -- Alba Therapeutics Corporation today announced the promotions of Linda Arterburn, PhD, Francisco Leon, MD, PhD, Roberto Allen, Esquire, Mark Ginski, PhD, and Kate Huber. "We are pleased to announce the promotions of several of our team members and we are fortunate to have such a fine group of talented people working here to help us develop medicines for unmet medical needs of patients with celiac disease, asthma, eye disorders, and other areas to treat autoimmune and inflammatory disease," said Bruce Peacock, CEO of Alba Therapeutics.

Linda Arterburn, PhD, has been promoted to Vice President of Preclinical Development and Program Management at Alba. Prior to joining Alba, Dr. Arterburn was Executive Director of Discovery Research at Market Biosciences. In this capacity, she initiated an inflammation research program and was lead inventor on two patents involving novel anti-inflammatory lipids. She previously led Clinical Research and Scientific Affairs at Market where she played a key role in the regulatory authorizations for the addition of Market's fatty acid products, DHA and ARA, to infant formula in the United States and Canada. Dr. Arterburn also spent seven years at W.R. Grace & Co., where she led an in vitro toxicology research program, and then served as Manager of Technology and Planning. Dr. Arterburn received her PhD in Pharmacology and the Molecular Sciences from the Johns Hopkins University School of Medicine, and her Bachelor's Degree in Biochemistry from the University of Wisconsin.

Francisco Leon, MD, PhD has been promoted to Vice President, Clinical Development and Medical Affairs. Dr. Leon is an immunologist with broad training in basic and clinical Immunology and a vocation for clinical development in the field of Mucosal Immunology. Prior to joining Alba, Dr. Leon was a Director of Clinical Development, Inflammatory and Respiratory Diseases at Med Immune where he worked on asthma and mucosal vaccination. He was a Director of Clinical Discovery, Oncology/ Immunology at Bristol-Myers Squibb where he worked on Crohn's disease, rheumatoid arthritis, and transplantation. Dr. Leon received his MD and PhD from Autonomy University, Madrid (Spain), and his PhD work was focused on the pathogenesis and diagnosis of Celiac disease. He completed a residency in Clinical Immunology at Ramon y Canal Hospital, Madrid where he was elected Resident of the Year in Spain in 2001 (Sanities Prize). Leon was a postdoctoral fellow in the Laboratory of Clinical Investigation (Mucosal Immunity Section) and in the Laboratory of Molecular Immunology (Mucosal Biology Section) of the National Institutes of Allergy and infectious Diseases, National Institutes of Health. He has authored or co-authored 60 original peer-reviewed articles, reviews, book chapters and patents.

Roberto Allen, Esquire has been promoted to Vice President, Legal Affairs and Intellectual Property at Alba. Prior to joining Alba, Mr. Allen was President of Respire Medical, Inc., a respiratory and home health care provider serving the Mid-Atlantic region. He was also Counsel at the Baltimore firm of Kollman & Saucier, P.A., where he practiced General Corporate and Labor & Employment law. Previously, he was a Senior Associate in the Business Department in the Baltimore office of Saul Ewing LLP. Mr. Allen is the Immediate Past President of the Baltimore Hispanic Chamber of Commerce and Past Chair of the Maryland Hispanic Business Conference. He currently serves on numerous community Boards of Directors and also serves as a Commissioner on the Maryland Commission on Human Relations. Mr. Allen received his B.S.E. degree in Electrical Engineering and Mathematics from Tulane University, an M.A. degree in Mathematics from the Johns Hopkins University and a J.D. from the University Of Maryland School Of Law.

Mark Ginski, PhD, has been promoted to Senior Director of Product and Analytical Development at Alba. Dr. Ginski's experiences include lead candidate selection, preformulation and formulation development, development, transfer and validation of analytical and bioanalytical methods, and packaging, labeling and distribution of clinical trial supplies. Prior to joining Alba, Dr. Ginski served as Associate Director of Preformulation Sciences at Shire where he played an integral role in developing and implementing Shire's Proscreen and Optiscreen programs designed to facilitate lead candidate selection and product development for both Shire's products as well as products from partnering companies. Additionally, he worked at Guilford Pharmaceuticals, where he was responsible for leading Exploratory Pharmaceutics and Chemistry, Manufacturing and Controls (CMC) programs for various preclinical and clinical development programs. Dr. Ginski holds a Ph.D. in Pharmaceutical Sciences from the University Of Maryland School Of Pharmacy and a Bachelors Degree in Biological Sciences from the University of Maryland. He has published numerous research and development articles and is an inventor for numerous global patents.

Kate Huber has been promoted to Director of Clinical Operations at Alba. Ms. Huber brings over 25 years of diverse experience in the health care industry and has been engaged in all aspects of the conduct of Phase I - Phase III clinical trials. She has worked in managing complex projects in the areas of celiac disease, oncology, CNS, vaccines, and diagnostics for HIV, HbsAg, and tuberculosis. Ms. Huber came to Alba from Nabi Biopharmaceutical and Guilford Pharmaceuticals where she had increasing responsibilities in the vaccine, oncology and CNS arenas. Kate has extensive experience in the diagnostic business and previously worked for Ortho Diagnostic Systems, Inc. and with Pharmacia where she helped develop diagnostic tools for pregnancy, HIV, Hepatitis B, and blood banking reagents. Ms. Huber received her MBA from Rider College in Lawrenceville, New Jersey, and her BA in Biology from Lycoming College in Williamsport, Pennsylvania.

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development, and commercialization of therapies to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Alba's technology platform is based upon a key pathway that regulates the assembly and disassembly of tight junctions in cell barriers throughout the body. As a result of its unique technology platform, Alba is a leader in mucosal biology and has developed a pipeline of innovative therapeutic candidates that has the potential to modify the course of disease and significantly improve upon existing treatments for a wide range of diseases such as Celiac disease, Crohn's disease, and Asthma/COPD or acute lung injury.

Contact: Wendy Perrow, MBA

Phone: 410-878-9850

E-mail: info@albatherapeutics.com

Web site: http://www.albatherapeutics.com


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):